Table 3.
Number of Patients With or Without Synchronous Brain Metastases at Diagnosis by Primary Cancer Site and Associated Unadjusted Median Survival Time in Months
| Cancer Site | All Cancer Patients (M0 and M1) Diagnosed 2010–2015 | M1 Patients With Brain Metastasis at Diagnosis | M1 Patients Without Brain Metastasis at Diagnosis | |||
|---|---|---|---|---|---|---|
| N | Median Survival, Months (95% CI) | N (%) | Median Survival, Months (95% CI) | N (%) | Median Survival, Months (95% CI) | |
| Lung and bronchus | 308 561 | 10 (10-10) | 33 668 (10.9%) | 4 (4-4) | 104 664 (33.9%) | 4 (4-4) |
| Small cell | 36 281 | 7 (7-7) | 5558 (15.3%) | 5 (4–5) | 17 790 (49.0%) | 5 (5-5) |
| Non-small cell | 272 280 | 11 (11-11) | 28 110 (10.3%) | 4 (4-4) | 86 874 (31.9%) | 4 (4-4) |
| Melanoma | 126 397 | NR (NR-NR) | 1595 (1.3%) | 5 (4–5) | 2918 (2.3%) | 12 (11–12) |
| Breast | 379 261 | NR (NR-NR) | 1562 (0.4%) | 9 (7–10) | 19 208 (5.1%) | 28 (28–29) |
| HR+/HER2- | 253 783 | NR (NR-NR) | 580 (0.2%) | 12 (10–15) | 9910 (3.9%) | 34 (33–35) |
| HR+/HER2+ | 36 458 | NR (NR-NR) | 225 (0.6%) | 20 (15–29) | 2543 (7.0%) | 43 (41–46) |
| HR−/HER2+ | 15 727 | NR (NR-NR) | 176 (1.1%) | 10 (8–14) | 1328 (8.4%) | 34 (30–41) |
| HR−/HER2− | 39 147 | NR (NR-NR) | 287 (0.7%) | 5 (4–6) | 2160 (5.5%) | 13 (12–13) |
| Unknown | 34 146 | NR (NR-NR) | 294 (0.9%) | 2 (2–4) | 3267 (9.6%) | 14 (13–15) |
| Kidney | 89 382 | NR (NR-NR) | 1253 (1.4%) | 4 (4–5) | 11 685 (13.1%) | 9 (9-9) |
| Colon and rectum | 223 842 | 70 (69-NR) | 573 (0.3%) | 4 (3–5) | 41 724 (18.6%) | 13 (13-13) |
| Esophagus | 24 033 | 11 (10–11) | 393 (1.6%) | 3 (3–4) | 6536 (27.2%) | 5 (5-5) |
| Stomach | 40 565 | 14 (14–15) | 253 (0.6%) | 3 (2–4) | 12 126 (29.9%) | 5 (5-5) |
| Prostate | 316 724 | NR (NR-NR) | 220 (0.1%) | 11 (9–14) | 17 136 (5.4%) | 26 (25–27) |
| Corpus and uterus, NOS | 80 623 | NR (NR-NR) | 186 (0.2%) | 3 (3–4) | 6073 (7.5%) | 12 (12–13) |
NR, not reached at the end of follow-up; HR, hormone receptor; HER2, human epidermal growth factor receptor 2.